New Experimental Molecule Shows Promise in Treating Aggressive Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer known for its high recurrence rates, metastasis, and mortality. Now, a new experimental molecule, SU212, developed by a U.S. Research team, offers a potential breakthrough in treatment.

Understanding Triple-Negative Breast Cancer

TNBC accounts for approximately 15% of all breast cancer cases [1]. Unlike other types of breast cancer, TNBC lacks common hormone receptors (estrogen and progesterone receptors) and HER2 receptors. This absence makes traditional targeted therapies less effective, presenting a significant challenge in treatment [1].

How SU212 Works

Researchers at Oregon Health & Science University discovered that SU212 blocks an enzyme crucial to cancer progression. The study, published in Cell Reports Medicine, found that SU212 binds to and promotes the breakdown of enolase 1 (ENO1) [1]. ENO1 is involved in intracellular glucose metabolism, and cancer cells often produce large quantities of this enzyme.

By disrupting ENO1, SU212 inhibits tumor growth and reduces cancer cell metastasis. This mechanism may be particularly relevant for patients with metabolic diseases like diabetes, as these conditions can affect blood sugar and cell metabolism [1].

Potential Beyond Triple-Negative Breast Cancer

The research team suggests that targeting ENO1 could have broader applications in cancer treatment. Potential applications extend to other cancer types, including glioma, pancreatic cancer, and thyroid cancer [1]. The androgen receptor (AR) is also highly expressed by TNBC tumor cells and plays a vital role in tumor progression [2].

Next Steps and Clinical Trials

The next phase involves advancing SU212 into human clinical trials. Before trials can begin, the molecule requires approval from the U.S. Food and Drug Administration (FDA) and substantial research investment [1]. Successful clinical trials could pave the way for new treatment options for various cancers.

Exosomes and TNBC Research

Recent research also highlights the role of exosomes in TNBC. Exosomes carry genomic information and influence tumorigenesis, metastasis, and drug resistance [4]. Studies are exploring exosome-based transcriptomic signatures to understand the tumor immune microenvironment and identify potential therapeutic targets [4], [3].